JP2013521314A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013521314A5 JP2013521314A5 JP2012556354A JP2012556354A JP2013521314A5 JP 2013521314 A5 JP2013521314 A5 JP 2013521314A5 JP 2012556354 A JP2012556354 A JP 2012556354A JP 2012556354 A JP2012556354 A JP 2012556354A JP 2013521314 A5 JP2013521314 A5 JP 2013521314A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- cancer
- pharmaceutical composition
- tigecycline
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 201000011510 cancer Diseases 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- 229960004089 tigecycline Drugs 0.000 claims 9
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 claims 8
- 108020005196 Mitochondrial DNA Proteins 0.000 claims 5
- 230000002438 mitochondrial effect Effects 0.000 claims 5
- 230000037396 body weight Effects 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 201000005787 hematologic cancer Diseases 0.000 claims 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 230000002601 intratumoral effect Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000008297 liquid dosage form Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000003928 nasal cavity Anatomy 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 239000005022 packaging material Substances 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- -1 tigecycline compound Chemical class 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31241010P | 2010-03-10 | 2010-03-10 | |
| US61/312,410 | 2010-03-10 | ||
| PCT/CA2011/000258 WO2011109899A1 (en) | 2010-03-10 | 2011-03-10 | Use of tigecycline for treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013521314A JP2013521314A (ja) | 2013-06-10 |
| JP2013521314A5 true JP2013521314A5 (enExample) | 2014-04-24 |
Family
ID=44562767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012556354A Withdrawn JP2013521314A (ja) | 2010-03-10 | 2011-03-10 | 癌の処置のためのチゲサイクリンの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20120329761A1 (enExample) |
| EP (1) | EP2544692A4 (enExample) |
| JP (1) | JP2013521314A (enExample) |
| CN (1) | CN102821769A (enExample) |
| CA (1) | CA2790240A1 (enExample) |
| WO (1) | WO2011109899A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2842228A1 (en) * | 2011-07-15 | 2013-01-24 | University Health Network | Combination treatment for cancer |
| WO2014029016A1 (en) * | 2012-08-24 | 2014-02-27 | University Health Network | Compositions comprising a glycylcycline and a tyrosine kinase inhibitor for treating cancer |
| PL2890673T3 (pl) | 2012-08-31 | 2019-06-28 | Tetraphase Pharmaceuticals, Inc. | Związki tetracyklinowe |
| EP3327144B1 (en) | 2013-02-25 | 2020-03-25 | Novartis AG | Novel androgen receptor mutation |
| CN103142624A (zh) * | 2013-03-01 | 2013-06-12 | 西南大学 | 抗生素替加环素在制备抗癌药物中的应用 |
| WO2014138338A1 (en) * | 2013-03-06 | 2014-09-12 | The General Hospital Corporation | Combinatorial compositions and methods for treatment of melanoma |
| SG11201901390TA (en) * | 2016-08-30 | 2019-03-28 | Tetraphase Pharmaceuticals Inc | Tetracycline compounds and methods of treatment |
| KR102660864B1 (ko) | 2016-10-19 | 2024-04-25 | 테트라페이즈 파마슈티컬스, 인코포레이티드 | 에라바사이클린의 결정질 형태 |
| WO2018213751A1 (en) | 2017-05-19 | 2018-11-22 | Lunella Biotech, Inc. | Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| CN109331026A (zh) * | 2018-04-21 | 2019-02-15 | 温州医科大学附属第医院 | 替加环素在制备抗多发性骨髓瘤药物中的应用 |
| US11441195B2 (en) | 2018-06-19 | 2022-09-13 | Lunella Biotech, Inc. | Energetic cancer stem cells (e-CSCs): a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837696A (en) * | 1997-01-15 | 1998-11-17 | The Research Foundation Of State University Of New York | Method of inhibiting cancer growth |
| WO2001035096A2 (en) * | 1999-11-10 | 2001-05-17 | Mitokor | Diseases associated with altered mitochondrial function |
| US20040253728A1 (en) * | 2000-11-10 | 2004-12-16 | Claes Gustafsson | New method |
| JP2005505588A (ja) * | 2001-10-05 | 2005-02-24 | テトラジェネックス ファーマスーティカルズ インク | テトラサイクリン誘導体、及びそれを使用する方法 |
| WO2004064728A2 (en) * | 2003-01-16 | 2004-08-05 | Paratek Pharmaceuticals, Inc. | Use of specific tetracycline compounds in therapy |
| US20050148553A1 (en) * | 2003-09-05 | 2005-07-07 | Testa Raymond T. | Use of tigecycline, alone, or in combination with rifampin to treat osteomyelitis and/or septic arthritis |
| AR057032A1 (es) * | 2005-05-27 | 2007-11-14 | Wyeth Corp | Tigeciclina y metodos de preparacion |
-
2011
- 2011-03-10 CN CN201180013184XA patent/CN102821769A/zh active Pending
- 2011-03-10 EP EP11752777.0A patent/EP2544692A4/en not_active Withdrawn
- 2011-03-10 JP JP2012556354A patent/JP2013521314A/ja not_active Withdrawn
- 2011-03-10 CA CA2790240A patent/CA2790240A1/en not_active Abandoned
- 2011-03-10 WO PCT/CA2011/000258 patent/WO2011109899A1/en not_active Ceased
- 2011-03-10 US US13/582,842 patent/US20120329761A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013521314A5 (enExample) | ||
| JP2013503824A5 (enExample) | ||
| US11224599B2 (en) | Therapeutic agents and methods | |
| JP2013512268A5 (enExample) | ||
| DOP2013000193A (es) | Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos | |
| ECSP12011703A (es) | Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos | |
| KR20170090408A (ko) | 벤조-헤테로시클릭 화합물 및 이의 적용 | |
| WO2015081133A3 (en) | Nucleotides for the treatment of liver cancer | |
| JP2017511321A5 (enExample) | ||
| CR20140197A (es) | Compuestos con actividad nematicida | |
| JP2013509429A5 (enExample) | ||
| AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
| NZ610851A (en) | Compounds and compositions for the treatment of cancer | |
| CY1117868T1 (el) | Νανοσωματιδια φορτωμενα με χημειοθεραπευτικο αντικαρκινικο φαρμακο | |
| SG10201810928SA (en) | Novel antitumoral use of cabazitaxel | |
| US11702443B2 (en) | Therapeutic agents and methods | |
| PH12016500885A1 (en) | Novel heterocyclic compounds | |
| CY1118559T1 (el) | 2,6-διαμινο-πυριμιδιν-5-υλο-καρβοξαμιδια ως αναστολεις των κινασων συκ ή jak | |
| Jha et al. | Curcumin-inspired cytotoxic 3, 5-bis (arylmethylene)-1-(N-(ortho-substituted aryl) maleamoyl)-4-piperidones: A novel group of topoisomerase II alpha inhibitors | |
| JP2015521195A5 (enExample) | ||
| JP2013537240A5 (enExample) | ||
| RU2013145869A (ru) | КОМБИНАЦИЯ ОЛИГОНУКЛЕОТИДА АНТИ-КЛАСТЕРИНА С ИНГИБИТОРОМ Hsp90 ДЛЯ ЛЕЧЕНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ | |
| WO2015009731A3 (en) | Azacyclic constrained analogs of fty720 | |
| WO2016003158A3 (ko) | DX2 단백질과 p14/ARF 단백질 간의 결합을 억제하는 신규 화합물 및 상기 화합물을 유효성분으로 함유하는 암질환 치료 또는 예방용 약학조성물 | |
| BR112014009288A2 (pt) | formas sólidas de 1,l-dioxo-4-tiomorfolinil)-[6-[[3(4-fluorofenil)-5-metil-4-isoxazolil]metóxi]-3-piridinil]-metanona |